Dernières nouvelles pour CureVac (NASDAQ:CVAC) Stock

CureVac

CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

CureVac NV

WIIM

AMRC

Ameresco shares are trading higher after the company reported better-than-expected Q1 financial results and issued FY25 guidance with its midpoint above estimates.

ARRY

Array Technologies shares are trading higher after the company reported better-than-expected Q1 sales results and issued FY25 adjusted EPS guidance with its midpoint above estimates.

JP Morgan analyst Pinjalim Bora maintains Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) with a Overweight and lowers the price target from $400 to $350.

News

Price Target

Analyst Ratings

MNDY

JP Morgan Maintains Overweight on Monday.Com, Lowers Price Target to $350

WeRide shares are trading higher after the company announced it expanded its strategic partnership with Uber to bring autonomous vehicles to 15 additional cities.

Wedbush analyst Michael Pachter downgrades Turtle Beach (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBCH#NASDAQ">TBCH</a>) from Outperform to Neutral and lowers the price target from $21 to $9.

Downgrades

TBCH

Wedbush Downgrades Turtle Beach to Neutral, Lowers Price Target to $9

Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) will receive $16 million in state incentives and tax breaks as the EV maker looks to expand its manufacturing unit in Illinois and build a supplier park.
What Happened: The company will receive the incentives from the local government, which includes tax breaks worth over $5 million from Illinois' REV (Reimagining Energy and Vehicles) program, according to a statement from the company on Monday.
Rivian is expected to invest $120 million to build the supplier park, which will help boost its lineup's production in the U.S. The supplier park is expected to span an area of 1.2 million square feet and will create hundreds of jobs, the company shared.
"We are excited to see this supplier park coming together so quickly. This will be a key enabler to increasing production at the plant in 2026 when we start to build R2 in addition to R1 and our commercial vans," Rivian CEO RJ Scaringe said.
Why It Matters: Rivian is gearing up for<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45205696/rivian-q1-earnings-preview-all-eyes-on-r2-launch-analyst-says-no-catalysts-in-2025"> its earnings call</a>, all set to take place on Tuesday. Analysts expect the company to share updates on the anticipated Rivian R2, which is the company's affordable 5-seater SUV.
Rivian also recently added AI expert and Coherent Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) co-founder Aidan Gomez to its <a href="https://www.benzinga.com/25/04/44934176/rivian-taps-ai-expert-aidan-gomez-to-drive-innovation-advanced-technology-integration">board of directors</a>, in a move that could help Rivian develop newer tech for its vehicles.
Elsewhere, Scaringe shared that Rivian's <a href="https://www.benzinga.com/tech/25/04/44836493/rivians-us-centric-supply-chain-could-offer-edge-amid-trumps-auto-tariffs-says-ceo-rj-scaringe">U.S.-centric supply chain</a> could help the company grapple with U.S. President Donald Trump&#8216;s tariffs and provide the EV maker an edge over its competitors.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="207" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06070926/RIVN-MAY-6-2025-1024x207.jpg" alt="" class="wp-image-903014" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06070926/RIVN-MAY-6-2025-1024x207.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06070926/RIVN-MAY-6-2025-300x61.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06070926/RIVN-MAY-6-2025-768x155.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06070926/RIVN-MAY-6-2025-1536x310.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06070926/RIVN-MAY-6-2025.jpg 1655w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Rivian scores well on Momentum and Growth metrics, and has a satisfactory score on the Value metric. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge</a> today!
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45130912/ford-pulls-the-plug-on-tesla-like-next-generation-electrical-architecture-for-evs-and-ice-vehicles-report">Ford Pulls The Plug On Tesla-like Next Generation Electrical Architecture For EVs And ICE Vehicles: Report</a></li>
</ul>
Photo courtesy: Michael Berlfein / Shutterstock.com

Markets

Tech

General

COHR

RIVN

Rivian To Receive $16 Million Incentive As Plans For $120 Million Illinois Supplier Park Take Shape

AHCO

AdaptHealth shares are trading higher after the company reported better-than-expected Q1 sales results.

ICHR

Ichor Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results and issued Q2 guidance below estimates.

LSI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYTS#NASDAQ">LYTS</a>), a leading U.S.-based manufacturer of commercial and industrial lighting and display solutions, announced the renewal of its partnership as an Official Lighting Sponsor of USA Pickleball. This extended collaboration highlights LSI's commitment to advancing America's fastest-growing sport through innovative lighting technologies that enhance visibility, safety, and the overall playing experience.

LYTS

LSI Industries Renews Partnership As Official Lighting Sponsor Of USA Pickleball

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)</h3>
<ul>
<li>Dividend Yield: 5.59%</li>
<li>Piper Sandler analyst David Amsellem reiterated a Neutral rating and cut the price target from $14 to $10 on March 5, 2025. This analyst has an accuracy rate of 73%.</li>
<li>B of A Securities analyst Jason Gerberry maintained an Underperform rating and slashed the price target from $11 to $10 on Feb. 28, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Recent News: On April 14, Viatris named Hemanth J. Varghese as Chief Strategy Officer.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506">VTRS news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506"><img loading="lazy" decoding="async" width="918" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49.png" alt="" class="wp-image-902820" style="width:634px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49.png 918w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49-768x701.png 768w" sizes="(max-width: 918px) 100vw, 918px" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.95%</li>
<li>Piper Sandler analyst David Amsellem initiated coverage on the stock with an Overweight rating and a price target of $65 on April 22, 2025. This analyst has an accuracy rate of 73%.</li>
<li>UBS analyst Trung Huynh maintained a Neutral rating and slashed the price target from $60 to $54 on April 11, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On April 24, Bristol Myers Squibb reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 billion.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506">latest BMY news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506"><img loading="lazy" decoding="async" width="907" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50.png" alt="" class="wp-image-902821" style="width:561px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50-768x714.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Premier, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>)</h3>
<ul>
<li>Dividend Yield: 4.10%</li>
<li>Baird analyst Eric Coldwell maintained a Neutral rating and cut the price target from $20 to $19 on Feb. 5, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Benchmark analyst Bill Sutherland downgraded the stock from Buy to Hold on Aug. 26, 2024. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: The company is expected to announce quarterly earnings today.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506">latest PINC news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506"><img loading="lazy" decoding="async" width="906" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51.png" alt="" class="wp-image-902822" style="width:579px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51-768x714.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

Trading Ideas

PINC

VTRS

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Neutral and raises the price target from $180 to $190.

JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $190

Marcus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCS#NYSE">MCS</a>) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 12.5 percent. This is a 42.11 percent decrease over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $148.77 million which beat the analyst consensus estimate of $139.89 million by 6.34 percent. This is a 7.38 percent increase over sales of $138.55 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Marcus Q1 EPS $(0.54) Misses $(0.48) Estimate, Sales $148.77M Beat $139.89M Estimate

Global Business Travel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTG#NYSE">GBTG</a>) lowers FY2025 sales outlook from $2.50 billion-$2.55 billion to $2.38 billion-$2.48 billion vs $2.54 billion estimate.

Guidance

GBTG

Global Business Travel Lowers FY2025 Sales Guidance from $2.50B-$2.55B to $2.38B-$2.48B vs $2.54B Est

OnKure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKUR#NASDAQ">OKUR</a>) reported quarterly losses of $(1.19) per share which beat the analyst consensus estimate of $(1.46) by 18.49 percent.

OKUR

OnKure Therapeutics Q1 EPS $(1.19) Beats $(1.46) Estimate

Global Business Travel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTG#NYSE">GBTG</a>) sees Q2 sales of $615.000 million-$635.000 million vs $652.62 million analyst estimate.

Global Business Travel Sees Q2 Sales $615.000M-$635.000M vs $652.62M Est

SEDG

SolarEdge Technologies shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance above estimates.

Capitolis Taps Pagaya, Goldman Sachs Veteran Amol Naik As Coo To Lead Growth Push

Peabody Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.22 by 22.73 percent. This is a 6.9 percent decrease over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $937.00 million which missed the analyst consensus estimate of $949.80 million by 1.35 percent. This is a 4.74 percent decrease over sales of $983.60 million the same period last year.

Peabody Energy Q1 EPS $0.27 Beats $0.22 Estimate, Sales $937.00M Miss $949.80M Estimate

JELD

JELD-Wen Holding shares are trading lower. The comapny issued Q1 financial results.

TCMD

Tactile Systems Technology shares are trading lower after the company reported worse-than-expected Q1 sales results and lowered its FY25 sales guidance below estimates.

Events

Press Releases

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

CureVac to Present at the 12th International mRNA Health Conference

Management

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

Comments

CureVac

Actualités

Dernières nouvelles pour CureVac (NASDAQ:CVAC) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL